Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 27, Issue 12, 2008, Pages 1183-1192

  Zhao, S ^a   Cheng, D ^a   Liu, E ^a   Yu, H ^b   Yang, H ^a   Xue, X ^a   Chu, Y ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DECOMPENSATED LIVER CIRRHOSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LOW DRUG DOSE; META ANALYSIS; MITOCHONDRIAL TOXICITY; MONOTHERAPY; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERFERONS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; TREATMENT OUTCOME;

EID: 56349098094     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-008-0557-8     Document Type: Article

References (31)

1. [No authors listed] 1999 EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver J Hepatol 30 956 961
2. GM Lauer BD Walker 2001 Hepatitis C virus infection N Engl J Med 345 41 52
3. TC Quinn J Overbaugh 2005 HIV/AIDS in women: an expanding epidemic Science 308 1582 1583
4. JK Rockstroh A Mocroft V Soriano C Tural MH Losso A Horban O Kirk A Phillips B Ledergerber J Lundgren EuroSIDA Study Group 2005 Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy J Infect Dis 192 992 1002
5. P Simmonds 1999 Viral heterogeneity of the hepatitis C virus J Hepatol 31 Suppl 54 60
6. NN Zein J Rakela EL Krawitt KR Reddy T Tominga DH Persing 1996 Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group Ann Intern Med 125 634 639
7. Chinese Society of Hepatology and Chinese Society of Lemology and Parasitology 2004 Guideline for prevention and treatment of hepatitis C in China Zhonghua Gan Zang Bing Za Zhi 12 194 199
8. C Lewden D Salmon P Morlat S Bévilacqua E Jougla F Bonnet L Héripret D Costagliola T May G Chêne Mortality 2000 study group 2005 Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS Int J Epidemol 34 121 130
9. EB Keefe 2003 Peginterferons in hepatitis C virus: virological, pharmacokinetic, and clinical implications. Introduction Semin Liver Dis 23 Suppl 1 1 2
10. MP Manns JG McHutchison SC Gordon VK Rustgi M Shiffman R Reindollar ZD Goodman K Koury M Ling JK Albrecht 2001 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 958 965
11. MW Fried ML Shiffman KR Reddy C Smith G Marinos FL Gonçales Jr D Häussinger M Diago G Carosi D Dhumeaux A Craxi A Lin J Hoffman J Yu 2002 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975 982
12. SJ Hadziyannis H Sette Jr TR Morgan V Balan M Diago P Marcellin G Ramadori H Bodenheimer Jr D Bernstein M Rizzetto S Zeuzem PJ Pockros A Lin AM Ackrill PEGASYS International Study Group 2004 Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346 355
13. AI Kim S Saab 2005 Treatment of hepatitis C Am J Med 118 808 815
14. M Egger G Davey Smith M Schneider C Minder 1997 Bias in meta-analysis detected by a simple, graphical test BMJ 315 629 634
15. R DerSimonian N Laird 1986 Meta-analysis in clinical trials Control Clin Trials 7 177 188
16. M Egger GD Smith AN Phillips 1997 Meta-analysis: principles and procedures BMJ 315 1533 1537
17. RT Chung J Andersen P Volberding GK Robbins T Liu KE Sherman MG Peters MJ Koziel AK Bhan B Alston D Colquhoun T Nevin G Harb C van der Horst AIDS Clinical Trials Group A5071 Study Team 2004 Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons N Engl J Med 351 451 459
18. FJ Torriani M Rodriguez-Torres JK Rockstroh E Lissen J Gonzalez-García A Lazzarin G Carosi J Sasadeusz C Katlama J Montaner H Sette Jr S Passe J De Pamphilis F Duff UM Schrenk DT Dieterich APRICOT Study Group 2004 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients N Engl J Med 351 438 450
19. A Cargnel E Angeli A Mainini G Gubertini R Giorgi M Schiavini P Duca Italian Co-infection Study (ICOS) Group 2005 Open, randomized, multicentre Italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART Antivir Ther 10 309 317
20. F Carrat F Bani-Sadr S Pol E Rosenthal F Lunel-Fabiani A Benzekri P Morand C Goujard G Pialoux L Piroth D Salmon-Céron C Degott P Cacoub C Perronne ANRS HCO2 RIBAVIC Study Team 2004 Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial JAMA 292 2839 2848
21. M Crespo S Sauleda JI Esteban A Juarez E Ribera AL Andreu V Falco J Quer I Ocaña I Ruiz M Buti A Pahissa R Esteban J Guardia 2007 Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients J Viral Hepat 14 228 238
22. M Laguno J Murillas JL Blanco E Martínez R Miquel JM Sánchez-Tapias X Bargallo A García-Criado E de Lazzari M Larrousse A León M Loncá A Milinkovic JM Gatell J Mallolas 2004 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients AIDS 18 F27 F36
23. AI Kim A Dorn R Bouajram S Saab 2007 The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis HIV Med 8 312 321
24. NJ Shire JA Welge KE Sherman 2007 Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis J Viral Hepat 14 239 248
25. S Zeuzem 2004 Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 140 370 381
26. AU Neumann NP Lam H Dahari M Davidian TE Wiley BP Mika AS Perelson TJ Layden 2000 Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus J Infect Dis 182 28 35
27. JM Pawlotsky C Hezode B Pellegrin A Soulier M Wagner JT Brouwer G Missale G Germanidis Y Lurie F Negro JI Esteban K Hellstrand C Ferrari S Zeuzem SW Schalm AU Neumann 2002 Early HCV genotype 4 replication kinetics during treatment with peginterferon alfa-2A (Pegasys)-ribavirin combination. A comparison with HCV genotypes 1 and 3 (abstract) Hepatology 36 291
28. AL Ballesteros S Franco D Fuster R Planas MA Martínez L Acosta G Sirera A Salas J Tor C Rey-Joly B Clotet C Tural 2004 Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches AIDS 18 59 66
29. C Hézode F Roudot-Thoraval ES Zafrani D Dhumeaux JM Pawlotsky 2004 Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections J Viral Hepat 11 455 458
30. E Voigt C Schulz G Klausen J Goelz S Mauss G Schmutz H Jessen L Weitner A Mutz D Schranz JK Rockstroh Kaad Study Group 2006 Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients J Infect 53 36 42
31. S Mauss JK Rockstroh 2005 HCV/HIV-coinfection-is there a state of the art after APRICOT and RIBAVIC? J Antimicrob Chemother 56 615 618